Comparison Between Volatile Anesthetic-desflurane and Total Intravenous Anesthesia With Propofol and Remifentanil on Early Recovery Quality and Long Term Prognosis of Patients Undergoing Pancreatic Cancer and Common Bile Duct Cancer Surgery
Pancreatic Cancer or Distal CBD Cancer
About this trial
This is an interventional other trial for Pancreatic Cancer or Distal CBD Cancer
Eligibility Criteria
Inclusion Criteria:
- Patients with ASA class I-III who are scheduled to undergo general anesthesia and who are diagnosed with pancreatic cancer or common bile duct cancer and who are scheduled for PPPD or distal pancreatectomy
- patients who voluntarily agree to participate the clinical study after fully informed and understood about the study
Exclusion Criteria:
- there was distant metastasis at the time of diagnosis
- history of drug adverse reaction or use of opioid or sedative drugs before the surgery
- patients who can not communicate enough to answer the survey
- obesity patients over BMI 30
- patient who are expected to maintain ventilator care on the first day of post operation due to the difficult to extubation right after the surgery
- patients who have inappropriate reasons to participate in clinical research
Sites / Locations
- Department of Anesthesiology and Pain Medicine Anesthesia and Pain Research Institute Yonsei University College of MedicineRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
DES Group
TIVA Group
Desflurane will be administered via tracheal intubation tube at the level of 0.7-1.1 MAC. Remifentanil will be maintained intravenously by continuous infusion rate of 0.01-0.1 mcg / kg / min DES Group's anesthetic depth will be adjusted to maintain the BIS (Bispectral index) between 40-60. Vital sign will be maintained within the range of ± 20% of the baseline MBP (Mean BP) and HR (Heart Rate).
Propofol and remifentanil will be administered via intravenous, using an infusion pump capable of effect site target controlled infusion. TIVA Group's anesthetic depth will be adjusted to maintain the BIS (Bispectral index) between 40-60. Vital sign will be maintained within the range of ± 20% of the baseline MBP (Mean BP) and HR (Heart Rate).